HOME >> BIOLOGY >> NEWS
Rensselaer marks the opening of the center for biotechnology and interdisciplinary studies

ed States Representative (N.Y.)

  • The Honorable Joseph L. Bruno, New York State Senate Majority Leader

  • The Honorable Elias Zerhouni, M.D., Director, National Institutes of Health

  • Bruce Alberts, Ph.D. President, National Academy of Sciences

  • Samuel Heffner Jr. '56, Chairman, Board of Trustees, Rensselaer Polytechnic Institute

  • Howard P. Isermann '42, Honorary Trustee, Rensselaer Polytechnic Institute

  • Robert E. Palazzo, Ph.D., Acting Director, Center for Biotechnology and Interdisciplinary Studies and Chair, Department of Biology, Rensselaer Polytechnic Institute

    "This extraordinary group of leaders in the sciences, engineering, business and government is rarely assembled in one place, and their participation is a testament to what the Rensselaer community has accomplished in a few short years," said Rensselaer President Shirley Ann Jackson. "By establishing the Center for Biotechnology and Interdisciplinary Studies, we have created a gathering place where scientists and engineers from various disciplines will explore at the intersection of the life sciences, with engineering and the physical and information sciences, thereby accelerating discovery and ultimately enhancing the quality of life for all people."

    Rensselaer's new center ranks among the world's most advanced research facilities focused on the application of engineering and the physical and information sciences to the life sciences. The Center for Biotechnology and Interdisciplinary Studies is a 218,000-square-foot, $100 million facility (including $80 million for construction). With its high-tech laboratories and expansive atrium, it provides a platform for collaboration among many diverse academic and research disciplines to enhance discovery and encourage innovation.

    The Center is designed to foster the multidisciplinary nature of biotechnology. It is organized around "constellations" of research Biocomputation and Bioin
    '"/>



  • Contact: Theresa Bourgeois
    bourgt@rpi.edu
    518-276-2840
    Rensselaer Polytechnic Institute
    2-Sep-2004


    Page: 1 2 3 4

    Related biology news :

    1. Rensselaer receives NIH grant to develop virtual surgery simulator
    2. New software developed at Rensselaer predicts promising ingredients for new drugs
    3. Rensselaer awarded $2.7 million NIH grant to improve drug development process
    4. National Institutes of Health grant to Rensselaer to further research on healing bone injuries
    5. Kimberly-Clark Worldwide donates intellectual property to Rensselaer
    6. Rensselaer effort to pull mussels at Lake George looks promising
    7. NASA Funds New Origin Of Life Center at Rensselaer Polytechnic Institute
    8. X marks the spot: Vector insertion is viral specific
    9. Despite darkness, nocturnal bees learn visual landmarks while foraging at night
    10. High Flux Isotope Reactor marks 400th cycle
    11. Study marks increased trends in infectious disease occurrences in our oceans

    Post Your Comments:
    (Date:7/23/2015)... (NASDAQ: AWRE ), a leading supplier of biometrics software ... ended June 30, 2015.  Revenue for the ... 33% compared to $6.8 million in the same quarter last ... $0.3 million, or $0.01 per diluted share, which compared to ... period a year ago.  Lower revenue and ...
    (Date:7/21/2015)... Passwords have proven futile for securing ... U.S. Office of Personnel Management breach. Biometric authentication ... but developers and end-users are concerned about how ... Biometrics-as-a-Service provider HYPR Corp. announced today the general ... party integration. A video overview ...
    (Date:7/9/2015)... 9, 2015  Synaptics Inc. (NASDAQ: SYNA ), a ... it will report financial results for the fourth quarter ... after the close of market. The company will host ... 2:00 p.m. PT (5:00 p.m. ET), during which management ... on the live call, analysts and investors should dial ...
    Breaking Biology News(10 mins):Aware, Inc. Reports Second Quarter 2015 Financial Results 2Aware, Inc. Reports Second Quarter 2015 Financial Results 3Aware, Inc. Reports Second Quarter 2015 Financial Results 4Aware, Inc. Reports Second Quarter 2015 Financial Results 5Aware, Inc. Reports Second Quarter 2015 Financial Results 6HYPR Corp. Launches Industry First Biometric Tokenization Platform 2HYPR Corp. Launches Industry First Biometric Tokenization Platform 3HYPR Corp. Launches Industry First Biometric Tokenization Platform 4Synaptics to Report Fourth Quarter, Fiscal Year 2015 Results on July 30 2
    (Date:7/30/2015)... ... July 31, 2015 , ... Ralco is honored to announce ... Lyon County Fair to be held August 5-9 in Marshall. The Ralco Enrichment Center ... come from and how agriculture impacts their daily lives. This unique exhibit also features ...
    (Date:7/30/2015)... Washington , July 30, 2015 ... Market, by Product (Software, Molecular Modeling, PB/PK, PKPD, Trial ... Discovery & Development, Preclinical, Clinical Trial), by End Users ... Biosimulation Market is expected to reach USD 2,107.99 million ... a CAGR of 15.29%. Browse more ...
    (Date:7/30/2015)... 2015 Ascendis Pharma A/S (Nasdaq: ... innovative TransCon technology to address significant unmet medical ... six-month Phase 2 study to evaluate the safety ... 53 treatment-naïve, pre-pubertal children with growth hormone deficiency, ... with the top-line results from our Phase 2 ...
    (Date:7/29/2015)... 2015 Sanofi, a global ... second quarter of 2015. CEO Olivier Brandicourt ... performance in different businesses. Watch video ... Topics covered in the interview ... - Performance drivers - Diabetes ...
    Breaking Biology Technology:Ralco Announces Primary Sponsorship of Ralco Enrichment Center at Lyon County Fair 2Biosimulation Market Worth 2,107.99 Million USD by 2020 2Biosimulation Market Worth 2,107.99 Million USD by 2020 3Biosimulation Market Worth 2,107.99 Million USD by 2020 4Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 5Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 6Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 7
    Cached News: